Dosing Guide for - GSK Source

For adult patients with bipolar I disorder *
Titration to target/maintenance dose:
For patients NOT TAKING carbamazepine, phenytoin,
phenobarbital, primidone, rifampin † , or valproate ‡§ :
Weeks 1-5
Patient
Titration Kit
(Orange)
Week 6 and onward
For patients TAKING valproate ठ:
Increase dose to 200 mg/day (target/maintenance dose)
For adult patients with bipolar I disorder *
Adjusting the dose of LAMICTAL ODT
When discontinuing other treatments:
For patients discontinuing valpro ate ठ:
Current dose of
LAMICTAL ODT
After discontinuation of valproate ठ:
Week 1
Week 2 onward
100 mg/day 150 mg/day 200 mg/day
Weeks 1-5
Patient
Titration Kit
(Blue)
Week 6 and onward
Increase dose to 100 mg/day (target/maintenance dose)
For patients TAKING carbamazepine, phenytoin, phenobarbital,
primidone, or rifampin † ,and NOT TAKING valproate ‡§ :
For patients discontinuing carbamazepine, phenytoin,
phenobarbital, primidone, or rifampin † :
Current dose of
LAMICTAL ODT
After discontinuation of carbamazepine, phenytoin,
phenobarbital, primidone, or rifampin † :
Week 1 Week 2 Week 3 onward
400 mg/day 400 mg/day 300 mg/day 200 mg/day
Weeks 1-5
Patient
Titration Kit
(Green)
Week 6
Increase dose to 300 mg/day
in divided doses
Week 7 and onward
Increase dose up to
400 mg/day in divided doses
(target/maintenance dose
• Doses above the target dose are not recommended.
• See Important Dosing Considerations on page 7 and Important
Safety Information on pages 14 and 15.
*See full indication on page 3.
† Carbamazepine, phenytoin, phenobarbital, primidone, and rifampin have been shown to
increase the apparent clearance of lamotrigine.
‡ Includes valproic acid and divalproex sodium.
§ Valproate has been shown to decrease the apparent clearance of lamotrigine.
When introducing other treatments:
• If other drugs are subsequently introduced, the doses of
LAMICTAL ODT may need to be adjusted. In particular, the
introduction of valproate requires reduction in the dose of
LAMICTAL ODT.
Please consult accompanying complete Prescribing Information for
LAMICTAL ODT, including Boxed Warning, and please see Important
Safety Information provided on pages 14 and 15.
DOSING FOR
PATIENTS WITH
BIPOLAR I DISORDER
10
11